Figure 1:SF-36 scores at baseline of the FLEXX Trial (week 0) for IA-BioHA– treated patients (blue) compared with the United States norms (black, age 55–64 years) and OA norms (grey). Compared with United States norms, the IA-BioHA group reported statistically significant lower scores in all domains except the MCS (P<0.05). Compared with OA norms, the IA-BioHA reported statistically significant lower scores in PF, RP, BP, and PCS but statistically significant higher scores in GH, VT, MH, and MCS (P<0.05). |